RU EN

Mon.-Fri.: 1000-1900

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

 

«A.Zalesov & Partners» Patent & Law Firm is a full-service IP law firm that gives IP advice, handles litigation (patents, trademarks and designs) and provides services in patent, design and trademark prosecution in the Russian Patent and Trademark Office and the Eurasian Patent Office. We handle our international clients' patent and trademark portfolios (including Madrid and Hague Systems of trademark and design registration) in Russia as well as in the neighboring countries, including the countries of the Eurasian Custom and Economic Union. Twenty years of experience in conducting patent and trademark disputes between leading players in the relevant markets in Russia and abroad enables us to give verified practical advice on IP protection, invalidation and enforcement strategy.

 

In focus

«Zalesov, Timofeev, Gusev & Partners» holds high positions in Kommersant's federal ranking

On April 24, 2025, Kommersant Publishing House published the results of the «Legal Services Market Leaders» ranking. «Zalesov, Timofeev, Gusev & Partners» Group has been recognized in seven practices in the federal ranking this year.

05.05.2025

Maria Makhlina performed as a guest expert at the MEPhI Science diplomacy club

On April 07, 2025, within the framework of the activities of the Science diplomacy club of MEPhI, a meeting of students with invited experts in the Career Talks format took place on the topic of intellectual property and patent law, where Maria Makhlina shared her experience in developing a patent strategy and patenting.

05.05.2025

Irina Ozolina commented to Kommersant publishing house on the mechanism of royalty payments under the so-called «compulsory licenses»

Irina Ozolina commented to Kommersant publishing house on issues related to the procedure for paying roaylties to patent holders in cases where the decision to use their inventions was made by the Government of the Russian Federation  (Article 1360 of the Civil Code of the Russian Federation). The publisher's question arose due to the fact that different manufacturers of semaglutide, who were granted the right to produce it by the Government decision, disagreed on how to determine the royalty rate due to the patent holder. Irina Ozolina explained the reasons for the discrepancies in the interpretation of regulatory legal acts.

15.04.2025